TX-MAVENIR
17.3.2022 14:03:02 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announces its complete Software as a Service (SaaS) based Business Communications portfolio, including customer engagement, business messaging, Communications Platform as a Service (CPaaS), Unified Communications as a Service (UCaaS) and Contact Center as a Service (CCaaS).
Mavenir leverages its global expertise in mobile networks, its relationships with hundreds of CSPs, enterprises and partners, and its leadership in the mobile messaging space to provide a Business Communications portfolio that enables omni-channel customer experiences to businesses of all sizes. The MAVbiz portfolio includes the following solutions:
> |
Mavenir Engage — Customer Engagement as a Service solution that combines multi-channel business messaging connectors (SMS, RCS, Apple Messages for Business, Google Business Messages) with business automations, chatbots, visual flow builder and campaign manager capabilities to enable conversational commerce capabilities for businesses of all sizes. |
||||
> |
Mavenir CPaaS — A full set of programmable APIs and turnkey applications (Smart 2FA, Number Masking, Call Routing) that allow businesses and developers to integrate communication capabilities into business processes and applications. |
||||
> |
Mavenir Connect — Unified Communication as a Service (UCaaS) solution that delivers a powerful set of high-definition voice, video, messaging, and meetings capabilities to allow workers to collaborate with colleagues and connect with customers anywhere, anytime and on any device. |
||||
> |
Mavenir Care — Contact Center as a Service (CCaaS) solution with omni-channel integrations, flexible and open APIs, business processes integrations (CRMs, AI platforms), visual IVR builder, and robust analytics and reporting. |
“Gartner predicts that 80% of customer service organizations will abandon mobile apps in favor of messaging by 2025i ," said Jorgen Nilsson, President, Enterprise Connect Business, Mavenir. “As a leader in messaging, with 60% SMS market shareii and over 3 billion mobile messaging subscribers globally, Mavenir is unlocking the power of business messaging to create a superior customer experience, leveraging our messaging footprint, certification as an Apple Messages for Business MSP and other key ecosystem partnerships.”
Mavenir’s Business Communications Solutions are designed to fit the needs of businesses of all sizes, micro, small and medium businesses to large enterprises, and are brought to market through CSPs, Channels or SIs, which can apply their own brand to the solutions and leverage Mavenir’s professional services, white-label marketing collateral, business operations and partner ecosystem relationships for fast time-to-market and subscriber growth.
Mavenir’s solutions deliver omni-channel interactions in every aspect of business communications and enable businesses with an affordable and fast enablement of their digital presence. By combining these solutions businesses can:
> |
Use Mavenir Engage chatbots and automations to offload repetitive tasks but leverage the human-in-the-loop (HITL) API to transfer messaging conversations to a representative using a Mavenir Care agent console |
||||
> |
Use Mavenir CPaaS APIs to send calls or text conversations from a business website or application to an employee using a Mavenir Connect endpoint. |
||||
> |
Transfer a customer call from the Mavenir Care agent console to another employee using a Mavenir Connect endpoint. |
||||
> |
Deflect incoming calls from the Mavenir Care contact center to a Mavenir Engage chatbot during busy hours or when the business is closed. |
Market dynamics are pointing towards omni-channel messaging in all aspects of business communication. 79% of consumers prefer live chats because they offer instant responsesiii and 53% of businesses saw an increase in workload due to the pandemiciv . Messaging increases productivity by allowing employees to handle multiple communications simultaneously.
Mavenir will be showcasing its Business Communications portfolio at Enterprise Connect 2022. Booth #1500 from March 21 to 24 in Orlando, Florida.
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
| ______________________________ |
i Source: Gartner Newsroom |
ii Source: Mavenir based on GSMA Operator Subscribers |
iii Source: 99 Firms – Live Chat Statistics |
iv Source: User Testing – 2021 CX Industry Report |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005116/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom